Sort
3,198 grants matching “mrna vaccine”
BCG efficacy against W-Beijing TB strains
$223,050Ian M Orme · Colorado State University · R21 · FY2015 · AI
Cancer therapy by targeting innate immune cells in vivo using novel virus-like particles
$222,998Dan S Kaufman · University Of California, San Diego · R21 · FY2025 · CA
Microvesicles as potential genetic biomarkers of brain tumors
$222,971Xandra Owens Breakefield · Massachusetts General Hospital · P01 · FY2012 · CA
Collaborative Research: Dynamics and Stability of Multi-Component Lipid Vesicles in Flow
$222,917Vivek Narsimhan · Purdue University · · FY2022 · ENG
Translational Control in Plasmodium Sexual Development
$222,883Pennsylvania State University-Univ Park · R01 · FY2004 · AI
The splicing factor SF3b1 is a master regulator of the innate immune response to Mycobacterium tuberculosis
$222,750Robert Owen Watson · Texas A&M University Health Science Ctr · R21 · FY2016 · AI
Translational Regulation of SARS-CoV-2 in response to viral S protein-induced signaling
$222,750Barsanjit Mazumder · Cleveland State University · R21 · FY2023 · AI
Models of Autoimmune Disease in a Genetically Defined Rabbit Breeding Colony
$222,624Rose Mage · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI
Pathological Implications of Repression of Cellular RNA Decay by Zika Virus
$222,436Jeffrey Wilusz · Colorado State University · R21 · FY2017 · AI
Extracellular vesicles encapsulating CRISPR machinery for treatment of SARS-CoV-2 infection
$221,972Houjian Cai · University Of Georgia · R21 · FY2023 · AI
Paramyxoviruses as Vaccine Vectors Against Highly Pathogenic Viruses
$221,905Ursula Buchholz · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
mRNA as a mediator of immunological information transfer in vivo
$221,751J. Lindsay Whitton · Scripps Research Institute, The · R21 · FY2015 · AI
Improving mRNA vaccines with extracellular vesicle-associated immunogens
$221,250Michael R. Farzan · Boston Children'S Hospital · R21 · FY2024 · AI
Innate resistance of CD4 T cells to HIV-1 infection in elite controllers
$221,250Mathias Lichterfeld · Massachusetts General Hospital · R21 · FY2012 · AI
Dendritic Cell Targeting Enhances Flavivirus Vaccine Efficacy
$220,970Gregg N. Milligan · University Of Texas Med Br Galveston · R21 · FY2008 · AI
Dendritic Cell Targeting Enhances Flavivirus Vaccine Efficacy
$220,970Gregg N. Milligan · University Of Texas Med Br Galveston · R21 · FY2009 · AI
MicroRNAs in dendritic cell differentiation and function
$220,890Xianzheng Zhou · University Of Minnesota · R21 · FY2011 · AI
Project 3: Modified RNA and LNP formulation as immunomodulatory agents for cellular immunity
$220,785Theresa M Raimondo · Brown University · P20 · FY2025 · GM
NOVEL VACCINE TARGETS FOR EARLY STAGE BREAST CANCER
$220,005Benaroya Research Inst At Virginia Mason · R01 · FY2000 · CA
Development and evaluation of a novel SOCS1-silenced HIV vaccine
$220,000Jerry L Blackwell · Emory University · R21 · FY2009 · AI
Regulation of Class I Gene Expressions in Tumor Cells
$219,835Virginia Commonwealth University · R01 · FY2002 · CA
Regulation of Class I Gene Expressions in Tumor Cells
$219,835Virginia Commonwealth University · R01 · FY2003 · CA
Regulation of Class I Gene Expressions in Tumor Cells
$219,835Virginia Commonwealth University · R01 · FY2001 · CA
Regulation of Class I Gene Expressions in Tumor Cells
$219,835Virginia Commonwealth University · R01 · FY2004 · CA
Regulation of Class I Gene Expressions in Tumor Cells
$219,835Virginia Commonwealth University · R01 · FY2005 · CA